Citigroup
VERV

Citigroup’s Verve Therapeutics VERV Stock Holding History

Citigroup’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-176,556
Closed -$1.98M – 6340
2025
Q2 		$1.98M Buy
176,556
+35,686
+25% +$203K ﹤0.01% 2657
2025
Q1 		$644K Buy
140,870
+22,436
+19% +$150K ﹤0.01% 3532
2024
Q4 		$668K Buy
118,434
+61,983
+110% +$350K ﹤0.01% 3628
2024
Q3 		$273K Buy
56,451
+14,288
+34% +$83K ﹤0.01% 4131
2024
Q2 		$206K Sell
42,163
-333,896
-89% -$2.1M ﹤0.01% 3857
2024
Q1 		$4.99M Buy
376,059
+232,344
+162% +$3.08M ﹤0.01% 1703
2023
Q4 		$2M Buy
143,715
+23,046
+19% +$286K ﹤0.01% 2237
2023
Q3 		$1.6M Buy
120,669
+31,126
+35% +$501K ﹤0.01% 2151
2023
Q2 		$1.68M Sell
89,543
-404,476
-82% -$6.74M ﹤0.01% 2376
2023
Q1 		$7.12M Buy
494,019
+328,340
+198% +$6.43M 0.01% 1311
2022
Q4 		$3.21M Sell
165,679
-2,041
-1% -$54.1K ﹤0.01% 1727
2022
Q3 		$5.76M Buy
167,720
+159,472
+1,933% +$5.09M ﹤0.01% 1469
2022
Q2 		$126K Sell
8,248
-30,424
-79% -$471K ﹤0.01% 4096
2022
Q1 		$882K Sell
38,672
-82,485
-68% -$2.36M ﹤0.01% 3086
2021
Q4 		$4.47M Buy
121,157
+119,343
+6,579% +$5.01M ﹤0.01% 1922
2021
Q3 		$85K Buy
+1,814
New +$107K ﹤0.01% 4475

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's VERV Position: Q3 2025 in Review

Citigroup sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 176,556 shares — an estimated $1.98M sold.

Citigroup first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $7.12M in Q1 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Citigroup reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 176,556 Verve Therapeutics shares in Q3 2025, an estimated $1.98M.
  • Citigroup first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Citigroup's Verve Therapeutics position peaked at $7.12M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.